Table 2.
The levels of PUFAs at week 12 from baseline between the EPA and placebo groups
| Mean (SD) | EPA (n = 45) | Placebo (n = 41) | P | ||||
|---|---|---|---|---|---|---|---|
| Baseline | Wk12 | Changes | Baseline | Wk12 | Changes | ||
| AA (%) | 9.91 (1.95) | 9.23 (2.54) | −0.68 (3.02) | 9.30 (2.93) | 8.50 (3.47) | −0.79 (4.44) | 0.887 |
| DHA (%) | 3.68 (0.98) | 3.59 (1.27) | −0.10 (1.49) | 3.49 (1.27) | 3.10 (1.42) | −0.45 (1.97) | 0.342 |
| EPA (%) | 1.18 (0.63) | 1.95 (1.12) | 0.77 (1.12) | 1.06 (0.37) | 0.91 (0.40) | −0.15 (0.62) | <0.0001**** |
| Total n-3 (%) | 5.56 (1.25) | 5.98 (2.10) | 0.48 (2.30) | 5.29 (1.55) | 4.49 (1.79) | −0.87 (2.58) | 0.012* |
| Total n-6 (%) | 27.58 (3.57) | 25.80 (4.50) | −1.78 (5.80) | 26.56 (5.69) | 24.78 (6.43) | −1.78 (8.40) | 0.999 |
| N-6/n-3 ratio | 5.17 (1.07) | 4.76 (1.58) | −0.43 (1.83) | 5.24 (0.97) | 6.23 (2.32) | 0.99 (2.73) | 0.008**# |
| hs-CRP (n = 43vs37) | 2.00 (0.90) | 1.98 (0.81) | −0.04 (0.38) | 2.27 (1.39) | 2.10 (1.15) | −0.10 (0.87) | 0.747 |
| BDNF (n = 44vs40) | 756.07 (394.99) | 74.43 (330.54) | −681.64 (344.42) | 771.00 (371.30) | −59.33 (289.54) | −824.80 (370.54) | 0.070 |
AA arachidonic acid, BDNF brain-derived neurotrophic factor, Changes indicates the changes of levels from baseline at week 12, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, hs-CRP high-sensitivity c-reactive protein, n number, n-3 omega-3 polyunsaturated fatty acids, n-6 omega-6 polyunsaturated fatty acids, SD standard deviation, wk week
Asterisk (*) indicates a statistical significance of p < 0.05
Asterisks (**) indicates a statistical significance of p < 0.01
Asterisks (****) indicates a statistical significance of p < 0.0001. The p values are from Independent-sample t-test, unless X2 test or Mann–Whitney test result
#Mann–Whitney test results
aX2 test results